Alexey Schulga - Search Results

Year	Number of Results
2002	1
2003	2
2004	2
2007	3
2008	2
2009	1
2010	1
2016	1
2017	1
2018	1
2019	6
2020	6
2021	5
2022	7
2023	3
2024	2

1

Switchable targeting of solid tumors by BsCAR T cells.

Stepanov AV, Kalinin RS, Shipunova VO, Zhang D, Xie J, Rubtsov YP, Ukrainskaya VM, Schulga A, Konovalova EV, Volkov DV, Yaroshevich IA, Moysenovich AM, Belogurov AA Jr, Zhang H, Telegin GB, Chernov AS, Maschan MA, Terekhov SS, Wu P, Deyev SM, Lerner RA, Gabibov AG, Altman S. Stepanov AV, et al. Among authors: schulga a. Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2210562119. doi: 10.1073/pnas.2210562119. Epub 2022 Nov 7. Proc Natl Acad Sci U S A. 2022. PMID: 36343224 Free PMC article.

2

On the prevention of kidney uptake of radiolabeled DARPins.

Altai M, Garousi J, Rinne SS, Schulga A, Deyev S, Vorobyeva A. Altai M, et al. Among authors: schulga a. EJNMMI Res. 2020 Feb 4;10(1):7. doi: 10.1186/s13550-020-0599-1. EJNMMI Res. 2020. PMID: 32020413 Free PMC article.

3

Accessing Mitochondrial Protein Import in Living Cells by Protein Microinjection.

Bogorodskiy A, Okhrimenko I, Maslov I, Maliar N, Burkatovskii D, von Ameln F, Schulga A, Jakobs P, Altschmied J, Haendeler J, Katranidis A, Sorokin I, Mishin A, Gordeliy V, Büldt G, Voos W, Gensch T, Borshchevskiy V. Bogorodskiy A, et al. Among authors: schulga a. Front Cell Dev Biol. 2021 Jul 7;9:698658. doi: 10.3389/fcell.2021.698658. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34307376 Free PMC article.

4

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer.

Guryev EL, Smyshlyaeva AS, Shilyagina NY, Sokolova EA, Shanwar S, Kostyuk AB, Lyubeshkin AV, Schulga AA, Konovalova EV, Lin Q, Roy I, Balalaeva IV, Deyev SM, Zvyagin AV. Guryev EL, et al. Among authors: schulga aa. Molecules. 2020 Sep 19;25(18):4302. doi: 10.3390/molecules25184302. Molecules. 2020. PMID: 32961731 Free PMC article.

5

Barnase encapsulation into submicron porous CaCO₃ particles: studies of loading and enzyme activity.

Yashchenok AM, Gusliakova OI, Konovalova EV, Novoselova MV, Shipunova VO, Abakumova TO, Efimova OI, Kholodenko R, Schulga AA, Zatsepin TS, Gorin DA, Deyev SM. Yashchenok AM, et al. Among authors: schulga aa. J Mater Chem B. 2021 Nov 3;9(42):8823-8831. doi: 10.1039/d1tb01315g. J Mater Chem B. 2021. PMID: 34633027

6

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer.

Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, Sörensen J, Zelchan R, Medvedeva A, Deyev S, Tolmachev V. Bragina O, et al. Among authors: schulga a. J Nucl Med. 2022 Apr;63(4):528-535. doi: 10.2967/jnumed.121.262542. Epub 2021 Aug 12. J Nucl Med. 2022. PMID: 34385343 Free PMC article. Clinical Trial.

7

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [^99mTc]Tc-ADAPT6 and [^99mTc]Tc-(HE)₃-G3, for Imaging of HER2-Positive Breast Cancer.

Bragina O, Chernov V, Schulga A, Konovalova E, Hober S, Deyev S, Sörensen J, Tolmachev V. Bragina O, et al. Among authors: schulga a. Cancers (Basel). 2023 Jun 11;15(12):3149. doi: 10.3390/cancers15123149. Cancers (Basel). 2023. PMID: 37370758 Free PMC article.

8

Effect of Surface Modification of Multifunctional Nanocomposite Drug Delivery Carriers with DARPin on Their Biodistribution In Vitro and In Vivo.

Novoselova M, Chernyshev VS, Schulga A, Konovalova EV, Chuprov-Netochin RN, Abakumova TO, German S, Shipunova VO, Mokrousov MD, Prikhozhdenko E, Bratashov DN, Nozdriukhin DV, Bogorodskiy A, Grishin O, Kosolobov SS, Khlebtsov BN, Inozemtseva O, Zatsepin TS, Deyev SM, Gorin DA. Novoselova M, et al. Among authors: schulga a. ACS Appl Bio Mater. 2022 Jun 20;5(6):2976-2989. doi: 10.1021/acsabm.2c00289. Epub 2022 May 26. ACS Appl Bio Mater. 2022. PMID: 35616387

9

Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells.

Xu T, Liu Y, Schulga A, Konovalova E, Deyev SM, Tolmachev V, Vorobyeva A. Xu T, et al. Among authors: schulga a. Oncol Rep. 2022 May;47(5):94. doi: 10.3892/or.2022.8305. Epub 2022 Mar 22. Oncol Rep. 2022. PMID: 35315504 Free PMC article.

10

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.

Xu T, Schulga A, Konovalova E, Rinne SS, Zhang H, Vorontsova O, Orlova A, Deyev SM, Tolmachev V, Vorobyeva A. Xu T, et al. Among authors: schulga a. Int J Mol Sci. 2023 Feb 2;24(3):2838. doi: 10.3390/ijms24032838. Int J Mol Sci. 2023. PMID: 36769161 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

40 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year